Atavistik Bio has successfully secured $160 million in a Series B financing round to advance its innovative pipeline of treatments for rare diseases. The funding, bolstered by a recent $40 million extension from RA Capital Management, will propel two lead candidates into clinical trials. These programs target hereditary hemorrhagic telangiectasia (HHT) and specific myeloproliferative neoplasms (MPNs), addressing significant unmet medical needs.
Strategic Investment to Fuel Clinical Advancement
The total $160 million round reflects strong investor confidence in Atavistik's unique approach to drug discovery. Bryan Stuart, the company's CEO, stated that the backing from a highly respected syndicate validates their selective allosteric programs. This additional capital provides a robust financial foundation to accelerate the development of potentially transformative therapies for patients with severe diseases.
New investor RA Capital Management joins a prestigious group that includes Nextech Invest, The Column Group, and Regeneron Ventures. Nandita Shangari of RA Capital expressed enthusiasm for supporting Atavistik's next growth phase, citing the company's experienced team and high-quality programs. This strategic investment underscores the perceived potential for Atavistik to create meaningful value in treating difficult diseases.
A Novel Approach for Hereditary Hemorrhagic Telangiectasia
The company's lead candidate, ATV-1601, targets Hereditary Hemorrhagic Telangiectasia, a severe inherited bleeding disorder affecting over 1.6 million people globally. HHT is characterized by abnormal blood vessel formation driven by the hyperactivation of the AKT1 enzyme. Currently, there are no approved therapies that address the underlying cause, leaving patients with only symptomatic treatments.
Atavistik aims to change this with ATV-1601, an oral allosteric inhibitor designed to selectively block AKT1. By targeting a distinct allosteric site on the enzyme, the drug offers a precise mechanism to control the root cause of HHT. The company hopes this approach will not only manage bleeding but also potentially alter the natural course of the disease.
The selectivity of ATV-1601 is a key differentiator, allowing it to spare closely related enzymes and avoid toxicities seen with broader pan-AKT inhibitors. This improved tolerability is crucial for chronic dosing and was supported by an encouraging safety profile in a prior Phase 1 oncology study. The drug is now poised to enter early-stage clinical trials specifically for patients with HHT.
Targeting the Root of Rare Blood Cancers
Beyond HHT, Atavistik is also advancing a program for myeloproliferative neoplasms, a group of rare chronic blood cancers. A significant portion of these patients have a specific driver mutation known as JAK2 V617F. This mutation is present in the vast majority of individuals with polycythemia vera and a large percentage of those with myelofibrosis.
Current treatments for MPNs often use pan-JAK inhibitors, which block both the mutated and normal versions of the JAK2 enzyme. This lack of selectivity can lead to hematological side effects and disrupt the production of healthy blood cells. Atavistik's candidate is designed to selectively target only the JAK2 V617F mutation, a more precise strategy.
By focusing exclusively on the mutant protein, Atavistik's therapy has the potential to reduce the disease-driving allele burden while preserving normal bone marrow function. This approach could lead to a disease-modifying impact and substantially improve long-term outcomes for patients. The Series B funding will enable the company to advance this promising program through clinical proof of concept.
With its successful $160 million financing, Atavistik Bio is strongly positioned to translate its pioneering science into clinical reality. The company's focus on selective allosteric inhibitors for HHT and MPNs represents a promising new frontier in treating rare diseases. This significant capital infusion will accelerate the development of therapies that could offer superior efficacy and tolerability for patients in need.